Peptifact

Ipamorelin Results: One Growth-Hormone Pulse in 40 Men, a Surgical Trial That Missed, and a Mouse Study That Added Fat

What ipamorelin has been shown to do in people: a 1999 infusion study in 40 healthy men that measured one growth-hormone pulse, a 2014 bowel-surgery trial with no significant benefit, and a second 320-patient trial never reported. No human study has measured muscle, fat, sleep or skin. The animal work behind the fat-loss claim found the opposite in mice.

Robert F · Edited by Caroline S · Published 2026-11-18

Illustration: A single, empty, clear glass vial on a cool grey slate surface, lit by soft daylight.
Illustration

Ipamorelin is sold mainly as one half of a pair, injected beside CJC-1295, and the results pages that rank for it describe what a buyer should notice week by week. Google's AI summary for "ipamorelin results", captured on 18 November 2026, set out a five-stage timeline: sleep in weeks 1 to 3, energy in weeks 3 to 4, strength in weeks 4 to 8, "noticeable reductions in body fat" in weeks 8 to 12, and "full benefits" at three to six months, with users said to "drop 5–10% in body fat". Its sources were clinic blogs, a vendor's guide and a results page hosted on the website of a European natural-history consortium, a page unrelated to that organisation's subject.

None of those stages comes from a study of ipamorelin. This page sets out what has been measured instead, in whom, and what has not. What ipamorelin is and how it was developed is on Peptide Lexicon's ipamorelin entry. The harms are counted on our ipamorelin side-effects page, and the dose figures from the trials are on our CJC-1295 and ipamorelin dosage page.

Every human result, in one table

A PubMed search for "ipamorelin" returned 55 records on 18 November 2026. Most are animal pharmacology, chemistry, doping-test methods and reviews. Two report ipamorelin given to people as a study intervention. A third trial is registered but has never reported.

Study Who What was given What was measured Result
Gobburu et al. 1999 (PMID 10496658) Healthy men, 8 per dose level, 5 levels One 15-minute intravenous infusion Drug levels and growth hormone over hours One growth-hormone pulse at every dose, peak at 0.67 h, then back to negligible
Beck et al. 2014 (PMID 25331030, NCT00672074) 114 evaluable adults after bowel resection 0.03 mg/kg intravenously twice daily, up to 7 days Time to a tolerated solid meal 25.3 h vs 32.6 h on placebo, p = 0.15; no significant difference
NCT01280344 (Helsinn, 2011 to 2014) 320 adults after bowel resection Three intravenous regimens vs placebo Recovery of gut function, up to 10 days Never posted or published (registry last updated April 2017)

A fourth registry record, NCT07717866, names ipamorelin only as one ingredient of a "physiological supplementation" programme alongside testosterone, anastrozole, gonadorelin and vitamins, in an observational study of ibogaine, 5-MeO-DMT and brain stimulation in combat veterans. Whatever it finds about PTSD cannot be attributed to ipamorelin.

Every human dose in the record was intravenous. None was the daily subcutaneous injection the product is sold for.

The one hormone study, read closely

The 1999 study, run with Novo Nordisk, the company that discovered ipamorelin, is the basis for the claim that ipamorelin "raises growth hormone in humans". It does show that. What it shows is narrower than the claim usually implies.

  • The doses were 3 to 100 µg/kg. The paper gives them in nanomoles: 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg. At ipamorelin's molar mass of 711.9 g/mol (PubChem), those come to 3.0, 10.0, 30.0, 60.0 and 100.0 µg/kg (our arithmetic). The 0.03 mg/kg used in the later surgical trial is the middle level of this study.
  • The response was one pulse, not a raised level. At every dose, growth hormone rose once, peaked at 0.67 hours and declined to "negligible" concentrations. The drug's own half-life was 2 hours.
  • People varied more than the drug did. The authors reported that variation between individuals was larger for the hormone response than for blood levels of ipamorelin, so the same dose produced different growth-hormone responses in different men.
  • IGF-1 was not reported. IGF-1 is the growth-hormone-driven marker that clinics usually test. The abstract reports only ipamorelin and growth hormone concentrations.

Forty men, one infusion each, measured for a few hours. That is the whole human record of ipamorelin as a growth-hormone drug. The CJC-1295 half of the usual pair has a larger hormone record, set out on our CJC-1295 results page, but its trials also stopped at hormone levels.

The trial that was meant to show a benefit

Helsinn, the Swiss company that sponsored the human trials, tested it for postoperative ileus, the slowdown of the gut after abdominal surgery. Ghrelin-receptor drugs speed up gut movement, and in a rat model of the condition, intravenous ipamorelin shortened the time to the first bowel movement and, given repeatedly, raised food intake and body weight gain (Venkova et al. 2009, PMID 19289567).

In the published phase 2 trial, 117 patients were enrolled at hospital sites and 114 were analysed. On the key endpoint, the median time from first dose to tolerating a standard solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo. That is 7.3 hours, or 22% faster (our arithmetic), but with p = 0.15 the difference could be chance. The authors concluded that there were "no significant differences" on the key and secondary efficacy analyses. They described the study as small and the patients as varied.

Helsinn then ran a larger dose-finding trial in 320 patients, testing a double dose and a three-times-daily schedule. It finished in May 2014. Twelve years on, ClinicalTrials.gov shows no results for it and PubMed holds no paper. The development programme did not go further. A trial that is completed but never reported cannot be counted as success or failure, but it was the trial built to settle the question, and its result is not public.

What the animal studies found, including the inconvenient one

Most results pages draw on animal work without saying so. Here is that work.

Study Animal Finding
Raun et al. 1998 (PMID 9849822) Rat pituitary cells, rats, swine Released growth hormone with potency similar to GHRP-6; unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol in swine
Johansen et al. 1999 (PMID 10373343) Adult female rats, 15 days Bone length growth rose from 42 to 52 µm/day at the top dose; body weight gain rose; total IGF-1 did not change
Svensson et al. 2000 (PMID 10828840) Adult female rats, 12 weeks Bone mineral content rose, but in proportion to bigger bones and body weight; bone density per volume unchanged
Lall et al. 2001 (PMID 11162489) GH-deficient and GH-intact mice Relative body fat increased after 2 weeks; food intake and leptin rose; growth hormone itself did not raise fat
Andersen et al. 2001 (PMID 11735244) Adult rats on high-dose steroids, 3 months Offset the steroid-induced loss of muscle strength and bone formation
Lu et al. 2024 (PMID 39043357) Ferrets given cisplatin Reduced chemotherapy-related weight loss by about 24% in the delayed phase; no effect on vomiting

The Lall study is the one most directly relevant to the claim that sells the product. It compared ipamorelin with growth hormone in the same mice. Growth hormone lowered relative fat in the GH-deficient animals and left it unchanged in the others. Ipamorelin increased fat-pad weight relative to body weight in both groups. The authors attributed this to a mechanism that does not depend on growth hormone and "may include increased feeding". That fits what a ghrelin-receptor drug is known to do: ghrelin is a hunger hormone, and the ferret study tested ipamorelin precisely to reduce weight loss.

None of this shows what happens in people. It does mean the fat-loss claim has no support in humans and runs against the animal data.

The clinic timeline, set beside the record

Three of the ranking pages were read in full on 18 November 2026.

  • Perfect B (Doral, Florida), on the CJC-1295 and ipamorelin pair: sleep improves at weeks 2 to 4; at months 2 to 3 "fat loss accelerates"; at months 4 to 6 skin elasticity, fine lines and hair "noticeably improve". The page cites no study for any of these stages.
  • Florida Weight Loss MD, on ipamorelin alone, says that studies "have not established predictable changes in sleep, muscle mass, body fat or recovery after 2, 4 or 8 weeks", and offers its week bands only as checkpoints for tracking.
  • Google's AI summary repeated the five-stage timeline and the "5–10% in body fat" figure, sourced to clinic pages, a vendor guide and the consortium-hosted page described above.

Against the table above, each stage of that timeline is either unmeasured (sleep, energy, strength, skin, hair) or contradicted by the only controlled comparison available (body fat, in mice). Most of the ranking pages also describe the CJC-1295 pair, not ipamorelin alone. No registered trial has tested the pair, so no result can be credited to either half. A related comparison of the two growth-hormone routes is on our ipamorelin vs sermorelin page, and MuscleLedger's CJC-1295 and ipamorelin stack page covers the gym framing.

What is not established

  • Any effect of subcutaneous use. Every human dose on record was intravenous.
  • Any effect over weeks. The longest human exposure was seven days, in hospital, after surgery.
  • IGF-1 in people. The marker clinics test is not reported in either published human abstract.
  • Body composition, strength, sleep, skin, hair or libido in any human study.
  • The result of the 320-patient trial. Completed in 2014, never reported.
  • Women. The hormone study enrolled only men; the surgical trial's abstract does not report results by sex.

How ipamorelin compares with other peptides on time to effect, where labels exist, is on our how long do peptides take to work page. What it costs, and why the price per milligram says nothing about what is in the vial, is on our ipamorelin cost page. Ipamorelin is not approved by FDA for any use, and FDA lists ipamorelin acetate among substances that may present significant safety risks in compounding, as our Category 2 list page sets out. Anyone considering it for a health reason should take that record to a doctor before acting on any timeline.

Sources and dates

  • Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999;16(9):1412–6. PMID 10496658. Abstract read 18 November 2026.
  • Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527–34. PMID 25331030. Abstract read 18 November 2026.
  • ClinicalTrials.gov API v2, records NCT00672074, NCT01280344 and NCT07717866, read 18 November 2026. An intervention search for ipamorelin returned these three.
  • Venkova 2009 (PMID 19289567), Raun 1998 (PMID 9849822), Johansen 1999 (PMID 10373343), Svensson 2000 (PMID 10828840), Lall 2001 (PMID 11162489), Andersen 2001 (PMID 11735244), Lu 2024 (PMID 39043357): abstracts read 18 November 2026.
  • PubMed E-utilities search "ipamorelin", 55 records, 18 November 2026.
  • PubChem compound 9831659 (ipamorelin), molecular weight 711.9, read 18 November 2026.
  • Drugs@FDA via openFDA (data updated 16 November 2026): no application with ipamorelin as an active ingredient; control search for macimorelin returned NDA 205598.
  • Google results and AI summary for "ipamorelin results", United States, captured 18 November 2026; Perfect B and Florida Weight Loss MD pages read in a headless browser the same day. alphamanclinic.com failed to load (connection error) and is not quoted.

Frequently asked questions

What results does ipamorelin produce?

In people, the measured result is a single rise in growth hormone after an intravenous dose, peaking about 40 minutes later and gone within a few hours (1999 study, 40 healthy men). The only efficacy trial, in patients recovering from bowel surgery, found no significant benefit over placebo. No human study has measured muscle, fat loss, sleep or skin on ipamorelin, so the week-by-week results quoted online have no trial behind them.

How long does ipamorelin take to work?

The growth-hormone pulse it causes peaks about 0.67 hours after a 15-minute infusion, according to the one human pharmacology study. How long it takes to change anything a person would notice has never been measured. Timelines of 'weeks 1 to 3' for sleep and 'weeks 8 to 12' for fat loss come from clinic and vendor pages, not from a study.

Does ipamorelin cause weight loss?

No human study has measured it. The closest evidence points the other way: in mice, twice-daily ipamorelin increased relative body fat after two weeks and raised food intake, while growth hormone itself did not (Lall 2001). In rats it increased body weight. Animal findings do not show what happens in people, but none supports the fat-loss claim.

Did ipamorelin work in clinical trials?

Its one published efficacy trial did not reach significance. In 114 patients after bowel resection, the median time to a tolerated meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a gap of 7.3 hours with p = 0.15. A larger follow-up trial of 320 patients finished in 2014 and its results have never been posted or published.

Is ipamorelin FDA approved?

No. Drugs@FDA held no application for it when searched on 18 November 2026, and neither the Novo Nordisk nor the Helsinn development programme reached approval. FDA lists ipamorelin acetate among bulk substances that may present significant safety risks in compounding.